Proteomic signature of Apolipoprotein J in the early phase of new-onset myocardial infarction.
2010, J Proteome Res. 2010 Nov 3. [Epub ahead of print]
Cubedo J, Padro T, Garcia-Moll X, Pinto X, Cinca J, Badimon L.
Related authors of the center Badimon Lina, Padró Teresa, Cubedo Judit.
Cubedo J, Padro T, Garcia-Moll X, Pinto X, Cinca J, Badimon L.
Related authors of the center Badimon Lina, Padró Teresa, Cubedo Judit.
Abstract
Acute myocardial infarction (AMI) is one of the major causes of mortality and morbidity worldwide. Despite all the efforts there is a lack of early markers for prevention, diagnosis and treatment of ischemic syndromes. By applying a proteomic expression profiling approach to identify biomarkers of early stages of AMI we have detected significant changes in Apolipoprotein J/clusterin (ApoJ) in patients with an acute new-onset myocardial infarction. Methods and results: ApoJ characterization by bidimensional electrophoresis (2-DE), followed by mass-spectrometry (MALDI-TOF) depicted a cluster of 13 spots (pI: 4.5-5.0, Mw: 37.1-47.3kDa) with a significantly different distribution between AMI-patients and controls. Specifically, spots 2, 3, 7, 10 and 13 showed a two fold increase in their intensity in AMI-patients (P=0.001). Western-Blot analysis (WB) for total serum ApoJ depicted two bands of 40-45kDa and 65-70kDa. When only glycosylated forms were analyzed the band of 65-70kDa was the most predominant one. A 25% decrease (P=0.05) of ApoJ glycosylated forms in AMI-patients was detected by 2-DE. Serum ApoJ levels, determined by a commercial ELISA, were significantly lower (P<0.001) in AMI-patients (n=39) immediately after the event than in controls (n=60). In 60% of patients, the lowest ApoJ level was detected within 6 hours after the onset of AMI. Between 72-96 hours after admission, ApoJ values in AMI-patients had reached control levels. Conclusions: Our results demonstrate alterations in ApoJ proteomic profile, due to a differential glycosylation pattern, in AMI-patients within the first 6 hours after the onset of the event. Therefore, the analysis of this isoform glycosylation shift in patients with AMI may be of better use to understand ApoJ function than the total serum levels of ApoJ and become an early marker of AMI.
PMID: 21043527 [PubMed - as supplied by publisher]
Acute myocardial infarction (AMI) is one of the major causes of mortality and morbidity worldwide. Despite all the efforts there is a lack of early markers for prevention, diagnosis and treatment of ischemic syndromes. By applying a proteomic expression profiling approach to identify biomarkers of early stages of AMI we have detected significant changes in Apolipoprotein J/clusterin (ApoJ) in patients with an acute new-onset myocardial infarction. Methods and results: ApoJ characterization by bidimensional electrophoresis (2-DE), followed by mass-spectrometry (MALDI-TOF) depicted a cluster of 13 spots (pI: 4.5-5.0, Mw: 37.1-47.3kDa) with a significantly different distribution between AMI-patients and controls. Specifically, spots 2, 3, 7, 10 and 13 showed a two fold increase in their intensity in AMI-patients (P=0.001). Western-Blot analysis (WB) for total serum ApoJ depicted two bands of 40-45kDa and 65-70kDa. When only glycosylated forms were analyzed the band of 65-70kDa was the most predominant one. A 25% decrease (P=0.05) of ApoJ glycosylated forms in AMI-patients was detected by 2-DE. Serum ApoJ levels, determined by a commercial ELISA, were significantly lower (P<0.001) in AMI-patients (n=39) immediately after the event than in controls (n=60). In 60% of patients, the lowest ApoJ level was detected within 6 hours after the onset of AMI. Between 72-96 hours after admission, ApoJ values in AMI-patients had reached control levels. Conclusions: Our results demonstrate alterations in ApoJ proteomic profile, due to a differential glycosylation pattern, in AMI-patients within the first 6 hours after the onset of the event. Therefore, the analysis of this isoform glycosylation shift in patients with AMI may be of better use to understand ApoJ function than the total serum levels of ApoJ and become an early marker of AMI.
PMID: 21043527 [PubMed - as supplied by publisher]
Catalan Institute of Cardiovascular Sciences
Hospital de la Santa Creu i Sant Pau, Pavelló del Convent
Sant Antoni Maria Claret, 167 08025 Barcelona
Spain
T: +34 - 93 556 5900 F: +34 - 93 556 5559